HPV Testing: Market Research Report Phone: +44 20 8123 2220 Fax: +44 207 900 3970 office@marketpublishers.com
HPV Testing: Market Research Report Date: January 4, 2015 Pages: 242 Price: US$ 4,950.00 ID: HCA569BED23EN This report analyzes the worldwide markets for HPV Testing in US$ Thousand. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 43 companies including many key and niche players such as - Abbott Molecular, Inc. Arbor Vita Corporation Becton, Dickinson and Company DaAn Gene Co., Ltd. F. Hoffmann-La Roche Ltd. Table of Content I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW HPV Testing Market Quick Facts Global HPV Testing Market: A Prelude Current and Future Analysis List of Select HPV Molecular Diagnostic Tests by Company and Technique Cervical Cancer: Rising Incidence & Mortality Enhances Need for Testing Major Risk Factors to HPV/Cervical Cancer Table 1. Number of New Cervical Cancer Cases in the World by Region and Age Group (2012) (includes corresponding Table 2. World Age-Standardized Cervical Cancer Incidence Rates (2012): Breakdown by Region (includes corresponding Table 3. Worldwide Cervical Cancer Mortality by Leading Countries (2012): Ranked by Number of Deaths (in 000s) (includes corresponding HPV Testing: Market Research Report 2
HPV Testing for Primary Screening Indication Bodes Well for the Market s Growth Table 4. Cervical Screening Penetration in Select Countries (2012): % of Women in 20-69 Age Group Screened for Cervical Screening(includes corresponding Developing Markets to Drive Global Growth Table 5. Number of HPV Tests by Geographic Region (2012) (In Million) (includes corresponding Table 6. Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Normal Cytology (includes corresponding Table 7. Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Cervical Cancer (includes corresponding C Countr Table 8. Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Low-Grade Lesions (includes corresponding mas Card Table 9. Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with High-Grade Lesions (includes corresponding ndian 14Latest Developments in HPV Testing Promise Bright Future Ahead Reimbursement Coverage Influences Adoption of HPV Testing HPV Vaccination Programs: Assessing the Impact on HPV Testing Market Some of the most common and rare side effects include: Gardasil - A Biohazard? Side-effects of Gardasil More Apparent among Preteens Inhalable Cervical Cancer Vaccines to Grow in Popularity HPV Vaccine Proves Beneficial in Prevention of Genital Warts in Men HPV Vaccination Initiatives in Select Countries HPV Vaccine Implementation: HPV Immunization Schedule and Population Coverage by Country 2. COMPETITIVE LANDSCAPE Qiagen, the Global Leader Face Headwinds from Roche Table 10. Assessing the Impact of FDA s Approval of Roche s HPV Test on HPV Sales of Market Majors: Y-O-Y Quarterly HPV Sales Growth for QIAGEN, Hologic and Rochea D90 Ha Table 11. Leading Players in the Global HPV Testing Market (2014E): Percentage Share Breakdown of Revenues for Abbott, Becton Dickinson, Hologic/Gen-probe, QIAGEN, Roche, and Others (includes corresponding r PaaS SComparative Analysis of HPV Testing Products A Review of Select HPV Tests digene HC2 HPV DNA Test digene HC2 High-Risk HPV DNA Test carehpv Test Cervista HPV HR Test Cervista HPV 16/18 Test Cobas 4800 HPV test HPV Testing: Market Research Report 3
Aptima HPV Assay 3. MARKET DYNAMICS HPV Testing: A Fast Growing Segment in the STD Diagnostic Testing Market Pap Cytology and HPV Co-testing: Improved Determination of Cervical Cancer Risk Cervical Cytology Screening: An Abstract Conventional Pap Smear Tests Give Way to Liquid-based Cytology Tests Table 12. Pap Tests Market in Select Countries (2014E): Percentage Share Breakdown of Number of Tests by Conventional Cytology Tests and Liquid-based Cytology Tests (includes corresponding Remains Table 13. Pap Smear Tests by Geography (2014E): Percentage Breakdown by Number of Tests for US, EU and Asia & Latin America (includes corresponding t of HeaNon-Invasive Urine HPV Test Holds Potential to Replace Pap Smear Test Cervical Cancer Screening: Focus on Detection of CIN2 and CIN3 Cancers Regular HPV Screening Enhances Treatment and Survival Options Need for Genotyping of HPV Subtypes Beyond 16 & Detecting E6 and E7 Oncoproteins to Improve Efficacy of Cervical Cancer Screening Novel Technological Developments to Enhance Accuracy of Screening Procedures Use of Non-FDA Approved Tests for HPV Testing: A Major Concern Increase in Instances of HPV-Linked Oral Cancer A Cause of Deep Concern Research Findings Indicate Two Vaccination Doses Equal Three Men Found to be More Susceptible to Oral HPV Infections 4. REGULATORY LANDSCAPE Favorable Guidelines: A Key Growth Driving Factor Recommendations of Interim Guidance Report Issued by SGO and ASCCP: Jan 2015 Capitulation of Cervical Cancer Screening Guidelines (2009-2012) Revised Guidelines for Cervical Cancer Screening: 2012 HPV Test to be a Part of the New Cervical Cancer Screening Guidelines in the US US Government Proposes Administration of HPV Vaccine for Males 5. OVERVIEW OF CYTOLOGY AND HPV TESTING What is HPV? Types of HPV Commonly Known Diseases and Related HPV Test Types Common Types of HPV Diseases Lung Cancer Cutaneous HPVs Genital HPVs Throat Cancer Causes of Infection Cervical Cancer and HPV HPV and Other Cancers Techniques for Detecting HPV Signal-Amplified Nucleic Acid Assays Target-Amplified HPV Assays What is HPV Testing? Test of HPV in Men HPV Testing: Market Research Report 4
Test of HPV in Women HPV Test Results Limitations of HPV Testing Advantages of HPV Testing Cervical Cytology Observation/Screening Pap Smear Screening Requirements for Pap Smear Test Advantages of Pap smear Test Limitations of Cytologic Screening HPV Testing vs. Cytology Testing 6. PRODUCT INTRODUCTIONS/APPROVALS Abbott Introduces RealTime High Risk HPV Test Advanced Cell Diagnostics to Introduce HPV Assay Based on RNAscope Technology Roche Receives US FDA Approval for cobas HPV Test for First-Line Primary Screening for Cervical Cancer in Women Cepheid Releases Xpert HPV Test for Cervical Cancer-Related HPV Qiagen Introduces carehpv Test in India BD Diagnostics Gains CE/IVD Marking for BD Onclarity HPV Assay Hologic Gains FDA Approval for Aptima HPV 16 18/45 Genotype Assay QIAGEN Launches carehpv Test in China Roche Seeks Initial Screening Indication for Cobas HPV Test Hologic Secures Approval for Aptima HPV Assay from US FDA Cancer Genetics Introduces FHACT Test CureHealth Diagnostics Unveils New HPV Detection Technology in India Abbott Rolls Out RealTime High Risk HPV Test in Canada Trovagene Launches HPV-HR Test Hologic Bags FDA Approval for Using APTIMA HPV 16 18/45 Genotype Assay with TIGRIS System FDA Grants Approval for Gen-Probe's PANTHER System GenPath Women's Health Rolls Out GenCerv HPV Test Seegene Unveils QuantPlex HPV28 Genotyping Assay QIAGEN Launches QIAensemble Decapper Sample Preparation Automation System in Europe 7. RECENT INDUSTRY ACTIVITY Cancer Genetics Acquires BioServe India Arbor Vita Enters into Distribution Agreement with AB ANALITICA Australian MSAC Recommends HPV Testing as Primary Cervical Cancer Screening Tool CytoCore Announces Name Change to MEDITE Cancer Diagnostics Enzo Ties up with IncellDx Inc IncellDx Inks Agreement with GeneCell Diagnostics IncellDx and Kindstar Global Ink Agreement Quest Diagnostics and Hologic Enter into Strategic Alliance QIAGEN and Calmette Hospital Enter into Partnership Hologic Acquires Gen-Probe QIAGEN Enters into Co-Marketing Agreement with KingMed Diagnostics Gynecor Implements cobas 4800 Analyzer for HPV Test Molecular Pathology Laboratory Network to Adopt Hologic/Gen-Probe APTIMA HPV Assay Trovagene Inks Agreement with Strand Life Sciences Bio-Reference Laboratories Acquires Stake in InCellDx QIAGEN Inks Co-Marketing Agreement with KingMed Diagnostics Roche Signs Agreement with Unilabs-IHS to Expand Access to HPV Testing in UK 8. FOCUS ON SELECT GLOBAL PLAYERS HPV Testing: Market Research Report 5
Abbott Molecular, Inc. (US) Arbor Vita Corporation (US) Becton, Dickinson and Company (US) DaAn Gene Co., Ltd. (China) F. Hoffmann-La Roche Ltd. (Switzerland) Hologic, Inc. (US) QIAGEN N. V. (The Netherlands) Seegene, Inc. (South Korea) 9. GLOBAL MARKET PERSPECTIVE Table 14. World Recent Past, Current and Future Analysis for HPV Testing by Geographic Region/ Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding High Mo Table 15. World Historic Review for HPV Testing by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Table 16. World 12-Year Perspective for HPV Testing by Geographic Region/Country - Percentage Breakdown of Revenues for US, Japan, Europe, and Rest of World Markets for Years 2009, 2015 & 2020 (includes corresponding III. MARKET 1. THE UNITED STATES Cervical Cancer in the US Key Statistics & Findings Table 17. Key Facts on Cervical Cancer in the US: 2014 Table 18. Prevalence of HPV in the US by Age (includes corresponding Table 19. Prevalence of HPV16 and HPV18 in the US by Cytology (2014) (includes corresponding Table 20. Number of New Cervical Cancer Cases by US State (2015) Table 21. Incidence and Mortality Rate of Cervical Cancer by Ethnicity in the US (2007-2011) (includes corresponding HPV Testing Market A Review Table 22. Cervical Cancer by HPV Type (2014E): Percentage Share Breakdown of Cervical Cancer Cases by HPV Type (includes corresponding Use of Non-FDA Approved Tests for HPV Testing: A Major Concern Competitive Landscape HPV Testing: Market Research Report 6
Table 23. Leading Players in the US HPV Testing Market (2013): Percentage Share Breakdown of Revenues for Hologic, QIAGEN, and Others (includes corresponding Cytology Testing Market An Insight Table 24. Pap Tests Market in the US (2014E): Percentage Share Breakdown of Number of Tests by Conventional Cytology Tests and Liquid-based Cytology Tests (includes corresponding HPV Vaccine Implementation Reimbursement of Screening Procedures Regulatory Landscape Recommendations of Interim Guidance Report Issued by SGO and ASCCP: Jan 2015 Overview of Cervical Cancer Screening Guidelines Revised Guidelines for Cervical Cancer Screening: 2012 2011: US GOVERNMENT PROPOSES ADMINISTRATION OF HPV VACCINE FOR MALES HPV Vaccine Implementation in the US Sates HPV Vaccines Legislations Passed by Individual US States (2011-2012) Product Introductions/Approvals Strategic Corporate Developments Key Players Table 25. US Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Table 26. US Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding 2. JAPAN Outlook Key Statistics in a Nutshell Table 27. Cervical Cancer in Japan (2014E): Percentage Share Breakdown of New Cases and Number of Deaths by Age Group (includes corresponding Table 28. Crude HPV Prevalence (%) in Women with Normal Cytology by Age Group (2014) (includes corresponding Table 29. Japanese HPV Market (2012): Leading HPV Types Causing Cervical Cancer (includes corresponding Japan Discontinues Recommendation of FDA Approved HPV Drugs Table 30. Japanese Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual HPV Testing: Market Research Report 7
Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Table 31. Japanese Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding 3. EUROPE Outlook Cervical Cancer Screening in Europe A Review Table 32. Key Facts on Cervical Cancer in Europe: 2014 (includes corresponding Table 33. Estimated New Cervical Cancer Cases per Year in Europe by Region and Age Group: 2012 (includes corresponding Table 34. Number of Deaths due to Cervical Cancer per Year in Europe by Region and Age Group: 2012 (includes corresponding Table 35. HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Normal Cytology (includes corresponding Table 36. HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Low-Grade Lesions (includes corresponding Table 37. HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with High-Grade Lesions (includes corresponding Table 38. HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Cervical Cancer (includes corresponding Table 39. Cervical Cancer Incidence and Mortality in European Countries (2012) (includes corresponding Table 40. Prevalence of Cervical Cancer in European Countries (2012) (includes corresponding Increasing Effectiveness of Cervical Cancer Screening Programs Need for Repeat Testing HPV The Preferred Primary Screening for Cervical Cancer in Europe Product Introductions/Approvals Table 41. European Recent Past, Current and Future Analysis for HPV Testing by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Table 42. European Historic Review for HPV Testing by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Table 43. European 12-Year Perspective for HPV Testing by Geographic Region/Country - Percentage HPV Testing: Market Research Report 8
Breakdown of Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2009, 2015 and 2020 (includes corresponding 3A. FRANCE Outlook Cervical Cancer in France A Review Table 44. Key Facts on Cervical Cancer in France: 2014 Table 45. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding HPV Vaccine Implementation Table 46. French Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Table 47. French Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding 3B. GERMANY Outlook Cervical Cancer in Germany A Review Table 48. Key Facts on Cervical Cancer in Germany: 2014 Table 49. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Table 50. German Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Table 51. German Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding 3C. ITALY Outlook Cervical Cancer in Italy A Review Table 52. Key Facts on Cervical Cancer in Italy: 2014 HPV Testing: Market Research Report 9
Table 53. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Strategic Corporate Development Table 54. Italian Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Table 55. Italian Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding 3D. THE UNITED KINGDOM Market Overview Cervical Cancer Key Statistics Table 56. Key Facts on Cervical Cancer in the UK: 2014 Table 57. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Impact of HPV Vaccine Implementation Strategic Corporate Development Table 58. UK Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Table 59. UK Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding 3E. REST OF EUROPE Outlook Spain Table 60. Cervical Cancer in Spain (2012): Percentage Share Breakdown of New Cases by Age-Group (includes corresponding Table 61. Key Facts on Cervical Cancer in Spain: 2014 Table 62. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Sweden Table 63. Key Facts on Cervical Cancer in Sweden: 2014 HPV Testing: Market Research Report 10
Table 64. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding The Netherlands Table 65. Key Facts on Cervical Cancer in the Netherlands: 2014 Table 66. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Russia Table 67. Key Facts on Cervical Cancer in Russia: 2014 Table 68. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Strategic Corporate Developments Key Players Table 69. Rest of Europe Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Table 70. Rest of Europe Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding 4. REST OF WORLD Outlook Focus on Select Markets Canada The Canadian Task Force on Preventive Health Care (CTFPHC) Recommendations for Cervical Cancer Screening: 2013 Table 71. Key Facts on Cervical Cancer in Canada: 2014 Table 72. Estimated Age-Standardized Incidence Rates of Cervical Cancer per 100,000 Women Population in Canada by Province (2014) (includes corresponding Table 73. Estimated Age-Standardized Mortality Rates of Cervical Cancer per 100,000 Women Population in Canada by Province (2014) (includes corresponding Table 74. Prevalence of HPV16 and HPV18 among Women in Canada by Cytology (2014) (includes corresponding Asia-Pacific Table 75. Key Facts on Cervical Cancer in Asia by Region: 2012 (includes corresponding HPV Testing: Market Research Report 11
Table 76. Incidence of Cervical Cancer in Asia by Region: 2012 (includes corresponding Table 77. Estimated New Cervical Cancer Cases per Year in Asia by Region and Age Group: 2012 (includes corresponding Table 78. Number of Deaths due to Cervical Cancer per Year in Asia by Region and Age Group: 2012 (includes corresponding Table 79. HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with Normal Cytology (includes corresponding Table 80. HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with Low-Grade Lesions (includes corresponding Table 81. HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with High-Grade Lesions (includes corresponding Table 82. HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with Cervical Cancer (includes corresponding China Introduction Table 83. Key Facts on Cervical Cancer in China: 2014 Table 84. Prevalence of HPV16 and HPV18 in China by Cytology (2014) (includes corresponding New Testing Technologies Gain Traction Competitive Landscape Table 85. Leading Players in China s HPV Market (2012): Percentage Share Breakdown of Value for Digene, Kaipu, Yaneng, Mingyuan and Others (includes corresponding India HPV Testing A Nascent Market TABLE 86: HPV Prevalence by Histology (includes corresponding Table 87. Prevalence of HPV Types 16 and 18 among Women in India - Breakdown by Cytology (includes corresponding Table 88. Top 10 HPV Oncogenic Types among Women in India (2012): Breakdown of Prevalence (%) by Cytology Table 89. Most Common HPV Oncogenic Types among Women with Invasive Cancer in India (2012): Breakdown of Prevalence (%) by Histology Cervical Cancer Screening in India - Still a Long Way to Go Table 90. Key Facts on Cervical Cancer in India: 2012 Table 91. Cervical Cancer Incidence and Mortality in India: 2012 HPV Testing: Market Research Report 12
Table 92. Estimated New Cervical Cancer Cases Per Year by Age Group in India (As of 2012) (includes corresponding Table 93. Number of Deaths due to Cervical Cancer per Year by Age Group in India (As of 2012) (includes corresponding Table 94. Crude Incidence Rate of Most Common Cancers among Women of all Ages in India: 2012 (includes corresponding Table 95. Crude Mortality Rate of Most Common Cancers among Women of all Ages in India: 2012 (includes corresponding Australia Table 96. Key Facts on Cervical Cancer in Australia: 2014 Table 97. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding National Cervical Screening Program Continues to Taste Success Cervarix and Gardasil to Combat Cervical Cancer New Zealand Table 98. Key Facts on Cervical Cancer in New Zealand: 2014 Table 99. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology Latin America Table 100. Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Normal Cytology (includes corresponding Table 101. Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Low-Grade Lesions (includes corresponding Table 102. Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with High-Grade Lesions (includes corresponding Table 103. Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Cervical Cancer (includes corresponding Brazil Table 104. Key Facts on Cervical Cancer in Brazil: 2014 Table 105. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding HPV Testing: Market Research Report 13
Mexico Table 106. Key Facts on Cervical Cancer in Mexico: 2014 Table 107. Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Africa Table 108. Key Facts on Cervical Cancer in Africa: 2014 Table 109. HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with Normal Cytology (includes corresponding Table 110. HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with Low-Grade Lesions (includes corresponding Table 111. HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with High-Grade Lesions (includes corresponding Table 112. HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with Cervical Cancer (includes corresponding Table 113. Cervical Cancer Incidence in Africa by Region: 2012 (includes corresponding Table 114. Estimated New Cervical Cancer Cases per Year in Africa by Region and Age Group: 2012 (includes corresponding Table 115. Number of Deaths due to Cervical Cancer per Year in Africa by Region and Age Group: 2012 (includes corresponding Table 116. Age-Standardized Cervical Cancer Incidence Rates in Africa by Region: 2012 (includes corresponding Table 117. Age-Standardized Cervical Cancer Mortality Rates in Africa by Region: 2012 (includes corresponding Product Launches Strategic Corporate Developments Key Players Table 118. Rest of World Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Table 119. Rest of World Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 43 (including Divisions/Subsidiaries - 48) The United States (22) HPV Testing: Market Research Report 14
Canada (2) Europe (13) France (1) Germany (1) The United Kingdom (2) Italy (2) Rest of Europe (7) Asia-Pacific (Excluding Japan) (11) HPV Testing: Market Research Report 15
Powered by TCPDF (www.tcpdf.org) Phone: +44 20 8123 2220 I would like to order: Product name: Product link: Product ID: Price: HPV Testing: Market Research Report /r/hca569bed23en.html HCA569BED23EN US$ 4,950.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com Payment To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page /r/hca569bed23en.html To pay by Wire Transfer, please, fill in your contact details in the form below: First name: Last name: E-mail: Company: Address: City: Zip/Post Code: Country: Tel: Fax: Your message: * All fields are required Customer Signature Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at /docs/terms_conditions.html To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970